A subset of obese individuals has significantly increased calorie intake, larger fasting gastric volume, and accelerated gastric emptying (GE) of solids.
individuals. 1 There is also evidence of variation in GLP-1 secretion in obesity after oral and small intestinal nutrient administration 6 ; the precise mechanism(s) associated with this difference is unclear.
GLP-1 receptor (GLP1R) agonists include short-acting, such as exenatide, and long-acting analogs, such as liraglutide. Participants treated with liraglutide experienced average weight loss of 8% after 6 months of treatment, with >10% body weight loss in 33% of participants; factors associated with greater weight loss are unclear. 7 In a randomized, placebo-controlled trial of liraglutide, 3.0 mg daily, in obese individuals, we recently reported that liraglutide delayed GE, and this was associated with weight loss with liraglutide over a 16-week treatment period. 8 Similarly, in a prior randomized, placebo-controlled trial of exenatide, 5 μg BID for 30 days, obese participants developed significant delay in GE, with non-significant higher weight loss with exenatide than placebo (P = .23). 9 Studies with liraglutide have shown that ~15% of patients lose >15% of body weight, and this is maintained over 1 or 3 years. 7 The reason(s) for the marked variation in weight loss in response to liraglutide treatment is unclear.
Our hypothesis was that the effect of GLP-1 agonists, such as exenatide and liraglutide, on weight loss may be affected by genetic variances of the GLP1R gene or the TCF7L2 gene. The rationale for selecting these genes and single-nucleotide polymorphisms (SNP)
is provided in the methods section. The aim of this pilot study was to assess whether specific genetic variants in GLP1R (rs6923761)
or TCF7L2 (rs7903146) are associated with prolongation of GE and weight loss in obese patients treated with exenatide or liraglutide.
| MATERIAL S AND ME THODS

| Overall design of trial, participants, and treatment
We evaluated the genetic variations of GLP1R and TCF7L2 from two different published studies 8, 9 involving single-center, doubleblinded, placebo-controlled, randomized clinical trials: the first
Key Points
• The aim of this pilot study was to explore whether specific genetic variants in GLP1R (rs6923761) or TCF7L2 (rs7903146) are associated with prolongation of gastric emptying and weight loss in obese patients treated with GLP-1 agonists (liraglutide and exenatide).
• A allele of GLP1R (rs6923761) is associated with a greater delay in gastric emptying in response to treatment with GLP-1 agonists.
• This study has acquired pilot data to plan a future study to assess the effect of genetic variability in GLP1R (rs6923761) on gastric emptying and weight loss in response to treatment with GLP-1 agonists. 
| Gastric-emptying measurement
Both studies utilized the same 296 kcal test meal and scintigraphic method to measure GE. Details are available elsewhere. 
| Statistical analysis
The genes were grouped into dominant (AA) and minor alleles (Aa/ aa) based on reported prevalence in the population from the NCBI database. 19 We used an intention-to-treat analysis with multiple imputations for any missing data. Our major outcomes were the changes in GE and weight loss at 5 weeks for liraglutide and at 30 days for exenatide studies. Firstly, we combined data from the two studies to assess effects of GLP-1 agonist or analog vs placebo.
In the genotype by treatment analysis, data from the two studies were assessed using three groups (liraglutide, exenatide, and the combined placebo group). Transformation to rank scale was used for change in weight (TCF7L2), but not for GLP1. For post-GE (eg, GE T 1/2 at 30 days), a proportional hazards' regression analysis was used to accommodate "censored" values. Analyses of the "interaction effects" of treatment by genotype were used for both changes in weight and GE T 1/2 . Data were reported as mean ± SEM. Figure 1 shows the CONSORT flowcharts and genotypes by treatment group for both exenatide and liraglutide studies. Genotyping for GLP1R rs6923761 was unavailable for one participant in the placebo group in the exenatide cohort. One participant in the liraglutide group refused genotyping. In our study, the overall allelic frequencies for GLP1R (GG 53.5%, AA_AG 46.5%) and TCF7L2
| RE SULTS
| Disposition
(CC 55.9%, TT_CT 44.1%) were similar to those reported in the literature.
The baseline demographics in the three groups (placebo vs liraglutide vs exenatide) were not significantly different ( Table 1) . In the exenatide group, we had preselected participants with accelerated GE (GE T 1/2 82.4 ± 5.1 minutes). The effects of these GLP-1 agents are published elsewhere. 8, 9 There was a significant correlation between the change in weight and GE at 30 days or 5 weeks (r s = −.382, P = .004; Figure 2 ).
| Effect of genetic variants on gastric emptying in response to exenatide and liraglutide
Data obtained by subdividing the groups by GLP1R (rs6923761) and TCF7L2 (rs7903146) genotypes are available in the Table S1 .
Within GLP1R (rs6923761), patients carrying the minor allele A (AA_AG) who received either exenatide or liraglutide had a numerically larger mean retardation in GE relative to baseline, 117.9 ± 27.5 minutes and 128.9 ± 38.3 minutes, respectively, compared to those with the dominant allele G (GG), 98.5 ± 30.4 minutes and 61.4 ± 21.4 minutes, respectively (P = .11). As seen in Figure 3A , the delay in GE was greatest in response to liraglutide in patients with the AA_AG genotype of GLP1R compared to the GG genotype.
There was a non-significant mean change in weight (Δ weight) at 5 weeks in the AA_AG group (−.9 ± 0.5 kg in the exenatide group and −3.5 ± 0.6 kg in the liraglutide group) compared to the GG group (−1.9 ± 0.4 kg in the exenatide group and −3.0 ± 0.5 kg in the liraglutide group; P = .62; Figure 3B ). 
| D ISCUSS I ON
In this study, we evaluated the potential impact of functional genetic variants of GLP1R (rs6923761) and TCF7L2 rs7903146 on the response to exenatide or liraglutide. Our data represent a 67.5-minute (~50%) difference in the mean change in GE in (AA_ AG) and (GG) subgroups based on the GLP1R (rs6923761) variants on treatment with liraglutide. Hence, we observed a numerically greater delay in GE in carriers of the minor variant (AA_AG) of GLP1R (rs6923761) in response to liraglutide. Although this difference was not statistically significant, a mean difference of 65 minutes (and median 25 minutes) is biologically relevant from the perspective of the association of delayed GE with satiation and, therefore, caloric intake since a 25-minute difference in GE T 1/2 would be associated with 80 kcal greater calorie intake in a buffet meal or nutrient drink test. 21 There was also a greater delay in the change in GE in the AA_AG compared to the GG group for exenatide (mean difference, 19.4 minutes), but not to the same degree observed with liraglutide.
Although we did not observe a substantial difference in weight loss at 5 weeks between AA-AG and GG GLP1R (rs6923761) genotype groups, this may reflect a type II error and the relatively short duration of the treatment trial.
Genetic variants of GLP-1R have been associated with changes in GLP1R function, 12 response to hypocaloric diets, 22 and response to treatment with liraglutide. 13, 23 Specifically, the minor variant allele (A) of GLP1R (rs6923761) has been associated with better anthropometric parameters after a hypocaloric diet for 
| Limitations
While we demonstrated a greater delay in GE in the minor variant allele (A) in GLP1R (rs6923761), our study was not powered to detect a pharmacogenetics association, and the observations were not statistically significant (P = .11). Based on the minor allele (A) frequency of ~36% in the population, 19 which is similar to the minor allele frequency in our patient population, we used the current data and calculated that a future study would conservatively require 70 patients with the minor variant (AA_AG) and 160 patients with the dominant variant (GG) to detect the clinically important difference in the effect of liraglutide on GE of 25 minutes.
Finally, the exenatide cohort was preselected for those with accelerated GE. In theory, these patients should have greater delay in GE after exposure to a GLP-1 agonist, but, in our cohort, the degree of change in GE among those with accelerated GE at baseline was similar to the delay observed in participants with normal GE at baseline.
In summary, the current pilot study supports the need for further studies to test the hypothesis that the minor variant allele (A) of GLP1R (rs6923761) plays a role in the response to GLP-1 agonists by delaying GE. This study also has provided the preliminary data on the coefficient of variation in responses in order to plan further evaluation of genetic variants of the GLP1R (rs6923761), GE, and weight 
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